Category Archives: Glucose Monitoring

New Implantable CGM Study from Indigo; Gilead/Novo Expand NASH Collaboration; Metacrine Q4 ’20 Earnings Update; Cytokinetics to Present GALACTIC-HF Analysis at ACC 2021

A series of cardiometabolic-related news items has been observed: Indigo Diabetes announced the first three participants in the GLOW early feasibility study have been implanted with Indigo’s “YANG sensor” for continuous glucose, ketone, and lactate monitoring; Gilead and Novo announced the companies have expanded their clinical collaboration in NASH following positive Ph2 POC data evaluating the combination of semaglutide+cilofexor+firsocostat; Metacrine hosted its Q4 and FY ’20 earnings call and provided development updates on MET642 and MET409 in NASH; and Cytokinetics announced a secondary analysis of GALACTIC-HF will be presented at ACC 2021 (May 15-17). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Zealand Q4 ’20 Earnings Update; Nemaura Submits for sugarBEAT Reimbursement in Germany

Two diabetes-related news items have been observed: Zealand hosted its Q4 and FY 2020 earnings call (press release; slides); and Nemaura announced it has submitted sugarBEAT for reimbursement in Germany. In case you missed it, FENIX provided coverage of Zealand’s R&D Day on March 5, 2021 (previous FENIX insight). Below FENIX provides highlights and insights from the respective news items, including an analysis on whether Beta Bionics, who is partnered with Zealand for dasiglucagon, would launch the insulin-only iLet configuration or if it would wait for the bi-hormonal system.

This content is for Read Less members only.
Already a member? Log in here

Senseonics Q4 ’20 Earnings Update; Provention Bio Extended Follow-up Data Published; Voluntis Collaborates with Zendesk for Global Customer Support

A series of diabetes-related news items have been observed: Senseonics hosted its Q4 and FY ’20 earnings call; Provention Bio announced the extended follow-up data from the pivotal “At-Risk” TN-10 Study has been published in Science Translational Medicine; and Voluntis announced a collaboration with Zendesk to upgrade its global customer support infrastructure. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

BI and Gubra Partner for Obesity Drug Development; Diabeloop DBLG1 Integrates with Accu-Chek Insight Pump; Tandem Appoints Jordan Pinsker as VP and Medical Director

A series of cardiometabolic-related news items have been observed: Boehringer Ingelheim and Gubra announced a research and licensing agreement for discovering and evaluating targets and innovative peptide compounds for the treatment of obesity; Diabeloop announced the integration of the Accu-Chek Insight insulin pump into the DBLG1 System; Tandem announced Jordan Pinsker from Sansum has been appointed as VP and Medical Director. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Lilly Partners with Welldoc for Connected Pen App

Lilly and Welldoc announced a partnership to integrate Welldoc’s diabetes software solutions with Lilly’s connected insulin delivery ecosystem. According to the press release, the companies will create a new version of Welldoc’s BlueStar app that integrates dosing data from “several of Lilly’s connected insulin pen solutions.” For context, the BlueStar app (view website) includes insulin titration support, a bolus calculator, and personalized health coaching. Below, FENIX provides an overview of the Lilly/Welldoc partnership, including thoughts on how the partnership supports FENIX’s hypothesis that Lilly’s connected pen development is further behind than initially thought.

This content is for Read Less members only.
Already a member? Log in here

Tandem and Teladoc Q4 and FY ’20 Earnings Updates

Tandem and Teladoc hosted their Q4 and FY ’20 earnings calls and provided updates on their respective businesses. Importantly, Tandem disclosed that the development of its next-gen t:sport pump platform has been delayed by one quarter. Below, FENIX provides highlights and insights from the respective calls.

This content is for Read Less members only.
Already a member? Log in here

Medtronic CY Q4 ’20 (FY Q3 ’21) Earnings Update

Medtronic hosted its CY Q4 ’20 (FY Q3 ’21) earnings call (press release; slides) and provided updates to its diabetes business across the 780G advanced hybrid closed-loop system (AHCL) and next-gen CGM platforms (Zeus and Synergy CGM). Below, FENIX provides highlights and insights from the call, including thoughts on Medtronic’s evolving CGM pipeline.

This content is for Read Less members only.
Already a member? Log in here

Biocorp Partners with Health2Sync and SocialDiabetes for Connected Pen Integration

Yesterday, Biocorp announced it has entered two diabetes-related partnerships with Health2Sync (view website) and SocialDiabetes (view website). For context, Mallya turns all disposable insulin pens into a connected device that collects dosing information and sends it to a companion app. Below, FENIX provides thoughts on the new Biocorp partnerships in the context of its existing partnerships (e.g. Roche, WaveForm, and Sanofi).

This content is for Read Less members only.
Already a member? Log in here

Nemaura Q4 ’20 earnings; MET409 POC Data Published in Journal of Hepatology

Two cardiometabolic-related news items have been observed: Nemaura Medical published its CY Q4 ’20 (FY Q3 ’21) earnings update and Metacrine announced the results of the MET409 proof-of-concept study were published in the Journal of Hepatology. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

AZ, DXCM, and Teva Q4 ’20 Earnings Updates; Supersapiens Partners with Ironman; Praluent Patent Litigation Upheld by US Court of Appeals; REGN Evinacumab Approved in US as Evkeeza; Former Novo Exec Hired as CMO for Hepion Pharma

Seven cardiometabolic-related news items have recently been observed from AstraZeneca, Dexcom, Supersapiens, Regeneron, Hepion Pharmaceuticals, and Teva. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here